Denny Lanfear: Thanks for the question. Theresa, could you address the generalized ability of the data question, please?
Theresa Lavallee: Yes. Things largely and both points are important, both the epidemiology of the disease, but also critically that there are no approved in the disease. So it’s both. And it’s a rare disease. So looking. The FDA has always looked at rare diseases. Yes. Thanks, Balaji. And both points are important. Both the epidemiology of the disease but also critically that there are no approved immunotherapies in the disease. So it’s both the – and it’s a rare disease. So looking the FDA has always looked at the rare disease populations and the ability to do multi-regional versus targeted trials as an approach to really look at drugs effect. The overall survival impact that has been observed is quite compelling. So it’s risk benefit, but it’s undeniable.
Operator: Thank you. Our next question comes from the line of Jason Gerberry with Bank of America. Please go ahead, Jason.
Jason Gerberry: Thank you for taking my questions. So, my question is just around the OpEx cuts there in any way related to any and be anticipated shortfall on revenue from the new launches in 2023 or 2024. And then my follow-up on Salim’s question is about NCCN and lung. Do you think the Toripalimab could garner much it’s in lung cancer? I just saw an NCCN recommendation. I’m not sure as they precedent two point here that mindful that you’re obviously not promoting for there. But I think with NCCN recommendation doctors can get reimbursement technically. So just kind of curious about that dynamic?
Denny Lanfear: Hi, thanks. I’ll take the first one with respect to the revenues. And then I’ll let Rosh Dias, our CMO address the NCCN. No, not so much a shortfall in revenue is driving the cost, but we felt that we needed to have the organization highly focused and right-sized and we felt that it was prudent for us and responsible to look for savings across the organization. We talked about this last year and developed savings in Q3 and Q4, which we disclosed. We told you, we’re going to go on and look for some more and we’ve gone ahead and we’ve done that. We run a very I think efficient company very tight ship all the expenditures are very closely scrutinized and we know what each single person in the company is doing and how they work together.
So we think it’s prudent. And lastly, I would say that, as I’ve said to you many times, we are very focused on driving towards profitability in 2024 and that means two things. That means, first of all, bringing up the revenue line with the additional products CIMERLI, UDENYCA, the additional presentations, Tori, YUSIMRY all across the board, raise the revenues and really control the costs without jeopardizing those revenues. And when those two lines intersect, we get the profitability. So that’s really our focus. With respect to NCCN, I’ll let Rosh address that question. Rosh?
Rosh Dias: Hi, Jason. Thanks. As I mentioned before to Salim, again we will wait for NPC approval. And then after that happens, we are able to submit additional data set. You asked specifically about lung was published I think back in the August timeframe in JCO. So once we have NPC approval, we will go ahead and submit and then see.
Operator: Thank you. Our next question comes from the line of Ash Verma of UBS. Please go ahead, Ash.
Ash Verma: Hi, thanks for taking my questions. I have two. So on the UDENYCA autoinjector injector, just curious like trying to understand how simple is this to use would this require kind of like any training for patient-physician, how do you foresee most of the initial used to happen. Would it be in the physician office setting or do you think patients can actually use this? And the second one, so we’ve seen like one biosimilar Humira competitor launch and they have two product offerings. Does that in anyway change your view in terms of either how pricing could evolve in this market or whether companies like yourselves would want to have two product strategy to come into the market? Thanks.
